AI is transforming industries, and biopharmaceuticals is no exception.

AstraZeneca is leading the way in utilizing AI to revolutionize biopharmaceutical research and development. With AI-enabled drug discovery systems, AstraZeneca reduces the timeline for creating novel therapeutic molecules from years to weeks, targeting diseases once deemed ‘undruggable’.

Its AI-driven platform spans the entire value chain—from early target identification and molecule design to optimizing clinical development and integrating real-world evidence—showcasing a comprehensive transformation rather than mere incremental advancements.

The company’s strategic embrace of AI is exemplified by its use of Gen AI to develop entirely new biologic molecules, such as antibodies and proteins with customized therapeutic properties. This groundbreaking capability is central to AstraZeneca’s innovation pipeline and competitive advantage.

With AI serving as a predictive and generative collaborator for researchers—enhancing human expertise without supplanting it—AstraZeneca is facilitating smarter molecule design, predictive safety assessments, and adaptive trial designs.

Dr. Santosh Karthikeyan Viswanathan, Global Technical Director of Clinical Data & Insights at AstraZeneca, will deliver a keynote at Tech & AI LIVE Singapore on November 4, 2025, discussing real-world AI applications in biopharma.

Secure your spot at Tech & AI LIVE Singapore here.

His session will explore how AI is transforming drug discovery, clinical trials, manufacturing efficiency, and patient outcomes, along with essential considerations for ethical AI adoption, data governance, model interpretability, and cross-functional collaboration in regulated environments.

AI-driven drug discovery

AstraZeneca’s approach to AI exemplifies the future of biopharmaceutical R&D: a data-driven, AI-augmented, scientifically rigorous model ready to deliver breakthrough therapies more quickly and reliably than ever, enhancing patient care globally.